Answers are grounded in this paper and cite their sources.
The patient showed a self-limiting trastuzumab-related thrombocytopenia. Among the reported cases of trastuzumab-induced severe thrombocytopenia, this patient is the only one who did not interrupt trastuzumab treatment. It is possible that our patient showed progressive reduction of immune-mediated thrombocytopenia caused by trastuzumab administration.
No takes yet. Share an insight, caveat, or question.
Mantzourani et al. (2011) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: